MicroVascular Therapeutics Licenses Patent from Triangle Biotechnology Inc.
MicroVascular Therapeutics (MVT), LLC, a privately-held Tucson-based biotechnology company, has licensed a patent from Triangle Biotechnology, Inc, entitled, "Formulation of acoustically activatable particles having low vaporization energy and methods for using same" (U.S. Patent No. 9,427,410, issued August 30th, 2016).
Phoenix, AZ, July 11, 2018 --(PR.com)-- MicroVascular Therapeutics, LLC (www.mvtpharma.com) MicroVascular Therapeutics (MVT), LLC, a privately-held Tucson-based biotechnology company, has licensed a patent from Triangle Biotechnology, Inc, entitled, "Formulation of acoustically activatable particles having low vaporization energy and methods for using same" (U.S. Patent No. 9,427,410, issued August 30th, 2016). Founders of MVT also previously developed Definity®, the world’s #1 selling ultrasound contrast agent. MVT is currently developing a new, improved ultrasound contrast agent referred to as MVT-100 via the 505(b)(2) pathway. In addition, MVT is developing targeted agents for molecular ultrasound imaging and theranostics to potentially treat diseases less invasively and more effectively using nanotechnology with ultrasound. Licensing the patent from Triangle Biotechnology, positions MVT to accelerate towards its vision of developing targeted therapy with ultrasound and nanotechnology.
Paul Dayton, PhD, Professor of Biomedical Engineering at the University of North Carolina, and co-inventor on the patent said, “This invention comprises a way of creating nanodroplets from pre-formed microbubbles, that remain stable after intravenous injection but revert to microbubbles when they enter the acoustic field of ultrasound. Since the nanodroplets are much smaller in diameter than microbubbles, this suggests that quite a number of additional diagnostic and therapeutic applications may be possible, including detection of myocardial scar and treatment of thromboses (e.g. heart attacks and stroke), drug and gene delivery.”
Wyatt Unger, MD, MBA, Chief Medical Officer of MicroVascular Therapeutics (MVT), said, “We are very pleased to license this patent. MVT is developing a new, improved ultrasound contrast agent called MVT-100 and has already developed nanodroplets based upon MVT-100. This patent will allow us to leverage our success in diagnostic echocardiography and develop therapeutic applications of nanodroplets based upon the technology that has been in-licensed. Under the terms of the license, MVT has secured a world-wide license for human, in vivo applications of nanodroplets based upon lipid-coated microbubbles.”
Dr. Thomas Porter, Theodore F. Hubbard Distinguished Chair of Cardiology at University of Nebraska, a recognized leader in applications of ultrasound contrast media added, “This patent that MVT has licensed has exciting potential. The ability to produce nanodroplets that retain their acoustic activity should be useful in the detection and treatment of a number of life-threatening diseases. For example, ultrasound can be used with microbubbles to treat myocardial infarctions (MI) and improve outcomes following heart attack. Nanodroplets, because of their smaller diameter should be able to better permeate the thrombus in the epicardial and microvascular regions, and further increase the beneficial effects of sonothrombolysis on treatment of MI.”
This therapy has the potential to radically alter the current treatment paradigm of MI by beginning treatment earlier, even in out of hospital settings, and improving cardiac function after MI. MVT plans to execute its clinical development program for developing therapeutic applications of nanodroplets in tandem with its diagnostic echocardiography platform. This in-licensed patent positions MVT as a leader in the fields of diagnostic echocardiography and sonothrombolysis in MI as well as in other therapeutic applications.
About MicroVascular Therapeutics (MVT)
MicroVascular Therapeutics is a biotechnology company based in Tucson, Arizona and is a leader in microbubble technology. MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease. The chemists at MVT have developed a new, patented formulation that may potentially serve as a platform for development of agents for molecular imaging and image-guided therapy. (www.mvtpharma.com)
About Triangle Biotechnology
Triangle Biotechnology, Inc., a privately held company based in Chapel Hill, NC, is developing novel technology for the improvement of acoustic processing of DNA, chromatin, and other biological samples for next generation sequencing and other diagnostic pipelines. (www.trianglebio.com)
For further information, please contact Jennifer Marshall (j.marshall@mvtpharma.com) at MicroVascular Therapeutics or Ricky McMahon (ricky.mcmahon@trianglebio.com) at Triangle Biotechnology.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Paul Dayton, PhD, Professor of Biomedical Engineering at the University of North Carolina, and co-inventor on the patent said, “This invention comprises a way of creating nanodroplets from pre-formed microbubbles, that remain stable after intravenous injection but revert to microbubbles when they enter the acoustic field of ultrasound. Since the nanodroplets are much smaller in diameter than microbubbles, this suggests that quite a number of additional diagnostic and therapeutic applications may be possible, including detection of myocardial scar and treatment of thromboses (e.g. heart attacks and stroke), drug and gene delivery.”
Wyatt Unger, MD, MBA, Chief Medical Officer of MicroVascular Therapeutics (MVT), said, “We are very pleased to license this patent. MVT is developing a new, improved ultrasound contrast agent called MVT-100 and has already developed nanodroplets based upon MVT-100. This patent will allow us to leverage our success in diagnostic echocardiography and develop therapeutic applications of nanodroplets based upon the technology that has been in-licensed. Under the terms of the license, MVT has secured a world-wide license for human, in vivo applications of nanodroplets based upon lipid-coated microbubbles.”
Dr. Thomas Porter, Theodore F. Hubbard Distinguished Chair of Cardiology at University of Nebraska, a recognized leader in applications of ultrasound contrast media added, “This patent that MVT has licensed has exciting potential. The ability to produce nanodroplets that retain their acoustic activity should be useful in the detection and treatment of a number of life-threatening diseases. For example, ultrasound can be used with microbubbles to treat myocardial infarctions (MI) and improve outcomes following heart attack. Nanodroplets, because of their smaller diameter should be able to better permeate the thrombus in the epicardial and microvascular regions, and further increase the beneficial effects of sonothrombolysis on treatment of MI.”
This therapy has the potential to radically alter the current treatment paradigm of MI by beginning treatment earlier, even in out of hospital settings, and improving cardiac function after MI. MVT plans to execute its clinical development program for developing therapeutic applications of nanodroplets in tandem with its diagnostic echocardiography platform. This in-licensed patent positions MVT as a leader in the fields of diagnostic echocardiography and sonothrombolysis in MI as well as in other therapeutic applications.
About MicroVascular Therapeutics (MVT)
MicroVascular Therapeutics is a biotechnology company based in Tucson, Arizona and is a leader in microbubble technology. MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease. The chemists at MVT have developed a new, patented formulation that may potentially serve as a platform for development of agents for molecular imaging and image-guided therapy. (www.mvtpharma.com)
About Triangle Biotechnology
Triangle Biotechnology, Inc., a privately held company based in Chapel Hill, NC, is developing novel technology for the improvement of acoustic processing of DNA, chromatin, and other biological samples for next generation sequencing and other diagnostic pipelines. (www.trianglebio.com)
For further information, please contact Jennifer Marshall (j.marshall@mvtpharma.com) at MicroVascular Therapeutics or Ricky McMahon (ricky.mcmahon@trianglebio.com) at Triangle Biotechnology.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Contact
MicroVascular Therapeutics LLC
Jennifer Marshall
520-624-6688
mvtpharma.com
Jennifer Marshall
520-624-6688
mvtpharma.com
Contact
Categories